Lupin Gets USFDA Nod for Generic HIV Drug
By Rediff Money Desk, New Delhi Jan 24, 2025 14:38
Lupin has received USFDA approval to market a generic HIV medication in the US market, under the PEPFAR program. The drug will be manufactured in Nagpur and supplied to low-and middle-income countries.

New Delhi, Jan 24 (PTI) Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market.
The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets, the Mumbai-base drug maker said in a statement.
The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension, it added.
This product would be manufactured at the drug firm's Nagpur facility and will be supplied to low-and middle-income countries, it said.
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg.
"The tentative approval from the USFDA for our Abacavir, Dolutegravir and Lamivudine Tablets enables us to improve the well-being of pediatric patients with HIV-1, thereby significantly boosting our HIV medication portfolio," Lupin Executive Director, Global CFO & Head of API Plus SBU Ramesh Swaminathan said.
Shares of Lupin were trading 0.78 per cent down at Rs 2,133.40 apiece on BSE.
The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets, the Mumbai-base drug maker said in a statement.
The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension, it added.
This product would be manufactured at the drug firm's Nagpur facility and will be supplied to low-and middle-income countries, it said.
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg.
"The tentative approval from the USFDA for our Abacavir, Dolutegravir and Lamivudine Tablets enables us to improve the well-being of pediatric patients with HIV-1, thereby significantly boosting our HIV medication portfolio," Lupin Executive Director, Global CFO & Head of API Plus SBU Ramesh Swaminathan said.
Shares of Lupin were trading 0.78 per cent down at Rs 2,133.40 apiece on BSE.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Quadrant Televenture
- 0.52 (+ 4.00)
- 15302442
- Vodafone Idea L
- 9.27 ( -2.11)
- 12924797
- Sunshine Capital
- 0.86 ( -4.44)
- 9764346
- Srestha Finvest
- 0.68 ( -1.45)
- 8590038
- Murae Organisor
- 1.85 (+ 4.52)
- 8336280
MORE NEWS

India & EFTA: Trade Boost, Investment, Business...
India sets up an EFTA desk to enhance trade and investment with the bloc. The move...
Rolls-Royce Doubles India Sourcing in 5 Years
Rolls-Royce plans to double its supply chain sourcing from India over the next five...

Rupee Hits Record Low of 87.95 Against US Dollar
Indian rupee plunges to a record low of 87.95 against the US dollar in early trade,...